- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02192788
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer
This study aims to probe the effect of SBRT as a treatment oligometastases of prostate cancer, regardless of basal treatment received, and I know the response, biochemical control, the progression-free survival as well as their impact on quality of life.
Primary Objective: Local and symptomatic oligometastases Control of prostate cancer treated by SBRT.
Secondary Objectives: Analyzing biochemical progression rates, progression-free survival, chemotherapy-free survival and overall survival. Analyze toxicities and quality of life of patients before and after treatment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Instituto Catalan de Oncologia
-
Bilbao, Spain
- Hospital de Cruces
-
Castellón De La Plana, Spain
- C.H.P. Castellón
-
Las Palmas De Gran Canaria, Spain
- Hospital Dr. Negrín
-
Madrid, Spain
- Hospital Ramón y Cajal
-
Madrid, Spain
- Hospital Universitario de La Princesa
-
Madrid, Spain
- Hospital Ruber Internacional
-
Madrid, Spain
- Clinica Quiron
-
Madrid, Spain
- Hospital Central de la Defensa Gómez Ulla
-
Madrid, Spain
- Hospital de Sanchinarro
-
Murcia, Spain
- Hospital Virgen de la Arrixaca
-
Navarro, Spain
- Hospital de Navarra
-
Salamanca, Spain
- Hospital Universitario Clinico de Salamanca
-
Santander, Spain
- Hospital Marques de Valdecilla
-
Valencia, Spain
- Hospital Universitari i Politecnic La Fe
-
Valencia, Spain
- ERESA H. General de Valencia
-
Vigo, Spain
- Hospital Do Mexoeiro
-
Zaragoza, Spain
- Hospital Miguel Servet
-
-
Las Rozas
-
Madrid, Las Rozas, Spain, 28290
- GICOR
-
-
Madrid
-
Majadahonda, Madrid, Spain
- Hospital Puerta de Hierro
-
Móstoles, Madrid, Spain
- Hospital Rey Juan Carlos
-
-
Murcia
-
Cartagena, Murcia, Spain
- Santa Lucia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically confirmed prostate cancer, who are currently being oligometastases / oligorrecurrencia after primary treatment for their disease.
- Aged ≥ 18 years
- Time to biochemical recurrence more than 1 year
- PSA doubling time> 3 months
- Less than 5 bone metastases location (including spinal) or lymph node.
- Without other metastases or recurrences by Choline PET or / and NMR Diffusion Length.
- Signed and dated written informed consent form.
Exclusion Criteria:
- Patients currently treatment with abiraterone, enzalutamide, chemotherapy, immunotherapy or radioisotopes.
- Patients unwilling or unable to comply with protocol requirements and scheduled visits.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SBRT
Stereotactic Body Radiation Therapy for Oligometastases (SBRT)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients without disease progression of prostate cancer treated by SBRT
Time Frame: 5 years
|
Number of patients without disease progression of local and symptomatic oligometastases of prostate cancer treated by SBRT expressed as total number and percentage
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival measured with Kaplan-Meier method
Time Frame: patients will be followed up an average of 5 years
|
the time to death will be defined as the time between the date when the patient is treated with SBRT and the date of death, or the last follow-up visit.
|
patients will be followed up an average of 5 years
|
Number of patients with an adverse events.
Time Frame: 3 months after the SBRT treatment
|
Analyze toxicities in every patient during the first 3 months after the treatment with SBRT.
Every significant Adverse Event will be graded as CTC-AE v.4.03.
For Pain related adverse events, visual analogic scale (VAS) will be used.
|
3 months after the SBRT treatment
|
Free disease progression survival measured with Kaplan-Meier method
Time Frame: the patients will be followed up an expected average of 5 years
|
the time to disease progression will be defined as the time between the date when the patient is treated with SBRT and the date of biochemical (PSA increased upper to 2 ng/mL) o radiological progression or the last follow-up visit.
|
the patients will be followed up an expected average of 5 years
|
Quality of life questionnaire FACT-P
Time Frame: baseline and 3rd month after the SBRT treatment.
|
The Functional Assessment Of Cancer Therapy-Prostate Questionnaire (FACT-P) will be performed at baseline and 3 months after the SBRT treatment.
|
baseline and 3rd month after the SBRT treatment.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Antonio J Conde Moreno, MD, Grupo de Investigación Clínica en Oncología Radioterapia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBRT-SG 05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oligometastatic Prostate Cancer
-
University of FloridaCompleted
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...The First Affiliated Hospital of Soochow University; The Affiliated Hospital... and other collaboratorsActive, not recruitingProstatectomy | Oligometastatic Prostate Cancer | AbirateroneChina
-
Universitaire Ziekenhuizen KU LeuvenRecruitingProstate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis | Oligometastatic Disease | Hormone Sensitive Prostate CancerBelgium
-
Technische Universität DresdenCompletedProstate Cancer | Oligometastatic DiseaseGermany
-
Azienda Ospedaliero-Universitaria CareggiNot yet recruitingOligometastatic Hormone Sensitive Prostate CancerItaly
-
Dr. Patrick CheungWithdrawnHormone Sensitive Oligometastatic Prostate CancerCanada
-
UNICANCERRecruitingOligometastatic Hormone Sensitive Prostate CancerFrance, Martinique
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate CarcinomaUnited States, Canada
-
European Institute of OncologyRecruitingOligometastatic Prostate CancerItaly
-
Centro di Riferimento Oncologico - AvianoRecruitingOligometastatic Prostate CancerItaly
Clinical Trials on Stereotactic Body Radiation Therapy for Oligometastases
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteCompletedLung CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedPain | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
Barts & The London NHS TrustBarts Cardiovascular CTU (Queen Mary University of London)Not yet recruitingHypertrophic CardiomyopathyUnited Kingdom
-
Erasmus Medical CenterCompletedKlatskin TumorNetherlands
-
Paul W. Read, MDUnknownMetastatic Bone LesionUnited States
-
University of FloridaCompletedSpinal TumorsUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingAdvanced Prostate CancerUnited States